Helicases as antiviral drug targets.
Identifieur interne : 003104 ( Main/Exploration ); précédent : 003103; suivant : 003105Helicases as antiviral drug targets.
Auteurs : J D Huang [Hong Kong] ; B J Zheng ; H Z SunSource :
- Hong Kong medical journal = Xianggang yi xue za zhi [ 1024-2708 ] ; 2008.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (pharmacologie), Cellules Vero (), Cellules Vero (cytologie), Cellules cultivées, Helicase (génétique), Helicase (pharmacologie), Réplication virale (), Réplication virale (génétique), Sensibilité et spécificité, Syndrome respiratoire aigu sévère (génétique), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Systèmes de délivrance de médicaments, Virus du SRAS (), Virus du SRAS (génétique), Évaluation préclinique de médicament.
- MESH :
- cytologie : Cellules Vero.
- génétique : Helicase, Réplication virale, Syndrome respiratoire aigu sévère, Virus du SRAS.
- pharmacologie : Antiviraux, Helicase.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Cellules Vero, Cellules cultivées, Réplication virale, Sensibilité et spécificité, Systèmes de délivrance de médicaments, Virus du SRAS, Évaluation préclinique de médicament.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Cells, Cultured, Chlorocebus aethiops, DNA Helicases (genetics), DNA Helicases (pharmacology), Drug Delivery Systems, Drug Evaluation, Preclinical, SARS Virus (drug effects), SARS Virus (genetics), Sensitivity and Specificity, Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (genetics), Severe Acute Respiratory Syndrome (virology), Vero Cells (cytology), Vero Cells (drug effects), Virus Replication (drug effects), Virus Replication (genetics).
- MESH :
- chemical , genetics : DNA Helicases.
- chemical , pharmacology : Antiviral Agents, DNA Helicases.
- cytology : Vero Cells.
- drug effects : SARS Virus, Vero Cells, Virus Replication.
- drug therapy : Severe Acute Respiratory Syndrome.
- genetics : SARS Virus, Severe Acute Respiratory Syndrome, Virus Replication.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Cells, Cultured, Chlorocebus aethiops, Drug Delivery Systems, Drug Evaluation, Preclinical, Sensitivity and Specificity.
Abstract
1. We have demonstrated for the first time that the helicase of a ribonucleic acid virus, the SARS coronavirus (SARS-CoV), is a valid target for drug development. 2. Using high throughput screen and chemical synthesis, several lead compounds targeting the SARS-CoV helicase have been identified. We have shown that these compounds can inhibit SARS-CoV helicase activity and viral growth in cell culture systems. These compounds can potentially be used to target other viruses.
PubMed: 18708673
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001999
- to stream PubMed, to step Curation: 001999
- to stream PubMed, to step Checkpoint: 001B24
- to stream Ncbi, to step Merge: 001D27
- to stream Ncbi, to step Curation: 001D27
- to stream Ncbi, to step Checkpoint: 001D27
- to stream Main, to step Merge: 003190
- to stream Main, to step Curation: 003104
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Helicases as antiviral drug targets.</title><author><name sortKey="Huang, J D" sort="Huang, J D" uniqKey="Huang J" first="J D" last="Huang">J D Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biochemistry, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong. jdhuang@hkucc.hku.hk</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Department of Biochemistry, The University of Hong Kong, 21 Sassoon Road, Pokfulam</wicri:regionArea><wicri:noRegion>Pokfulam</wicri:noRegion></affiliation></author><author><name sortKey="Zheng, B J" sort="Zheng, B J" uniqKey="Zheng B" first="B J" last="Zheng">B J Zheng</name></author><author><name sortKey="Sun, H Z" sort="Sun, H Z" uniqKey="Sun H" first="H Z" last="Sun">H Z Sun</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18708673</idno><idno type="pmid">18708673</idno><idno type="wicri:Area/PubMed/Corpus">001999</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001999</idno><idno type="wicri:Area/PubMed/Curation">001999</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001999</idno><idno type="wicri:Area/PubMed/Checkpoint">001B24</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B24</idno><idno type="wicri:Area/Ncbi/Merge">001D27</idno><idno type="wicri:Area/Ncbi/Curation">001D27</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D27</idno><idno type="wicri:doubleKey">1024-2708:2008:Huang J:helicases:as:antiviral</idno><idno type="wicri:Area/Main/Merge">003190</idno><idno type="wicri:Area/Main/Curation">003104</idno><idno type="wicri:Area/Main/Exploration">003104</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Helicases as antiviral drug targets.</title><author><name sortKey="Huang, J D" sort="Huang, J D" uniqKey="Huang J" first="J D" last="Huang">J D Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biochemistry, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong. jdhuang@hkucc.hku.hk</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Department of Biochemistry, The University of Hong Kong, 21 Sassoon Road, Pokfulam</wicri:regionArea><wicri:noRegion>Pokfulam</wicri:noRegion></affiliation></author><author><name sortKey="Zheng, B J" sort="Zheng, B J" uniqKey="Zheng B" first="B J" last="Zheng">B J Zheng</name></author><author><name sortKey="Sun, H Z" sort="Sun, H Z" uniqKey="Sun H" first="H Z" last="Sun">H Z Sun</name></author></analytic><series><title level="j">Hong Kong medical journal = Xianggang yi xue za zhi</title><idno type="ISSN">1024-2708</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Cells, Cultured</term><term>Chlorocebus aethiops</term><term>DNA Helicases (genetics)</term><term>DNA Helicases (pharmacology)</term><term>Drug Delivery Systems</term><term>Drug Evaluation, Preclinical</term><term>SARS Virus (drug effects)</term><term>SARS Virus (genetics)</term><term>Sensitivity and Specificity</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (genetics)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Vero Cells (cytology)</term><term>Vero Cells (drug effects)</term><term>Virus Replication (drug effects)</term><term>Virus Replication (genetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Cellules Vero ()</term><term>Cellules Vero (cytologie)</term><term>Cellules cultivées</term><term>Helicase (génétique)</term><term>Helicase (pharmacologie)</term><term>Réplication virale ()</term><term>Réplication virale (génétique)</term><term>Sensibilité et spécificité</term><term>Syndrome respiratoire aigu sévère (génétique)</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Systèmes de délivrance de médicaments</term><term>Virus du SRAS ()</term><term>Virus du SRAS (génétique)</term><term>Évaluation préclinique de médicament</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>DNA Helicases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>DNA Helicases</term></keywords><keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Cellules Vero</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Vero Cells</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term><term>Vero Cells</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Helicase</term><term>Réplication virale</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Helicase</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cells, Cultured</term><term>Chlorocebus aethiops</term><term>Drug Delivery Systems</term><term>Drug Evaluation, Preclinical</term><term>Sensitivity and Specificity</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Cellules cultivées</term><term>Réplication virale</term><term>Sensibilité et spécificité</term><term>Systèmes de délivrance de médicaments</term><term>Virus du SRAS</term><term>Évaluation préclinique de médicament</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">1. We have demonstrated for the first time that the helicase of a ribonucleic acid virus, the SARS coronavirus (SARS-CoV), is a valid target for drug development. 2. Using high throughput screen and chemical synthesis, several lead compounds targeting the SARS-CoV helicase have been identified. We have shown that these compounds can inhibit SARS-CoV helicase activity and viral growth in cell culture systems. These compounds can potentially be used to target other viruses.</div></front></TEI><affiliations><list><country><li>Hong Kong</li></country></list><tree><noCountry><name sortKey="Sun, H Z" sort="Sun, H Z" uniqKey="Sun H" first="H Z" last="Sun">H Z Sun</name><name sortKey="Zheng, B J" sort="Zheng, B J" uniqKey="Zheng B" first="B J" last="Zheng">B J Zheng</name></noCountry><country name="Hong Kong"><noRegion><name sortKey="Huang, J D" sort="Huang, J D" uniqKey="Huang J" first="J D" last="Huang">J D Huang</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003104 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003104 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:18708673
|texte= Helicases as antiviral drug targets.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:18708673" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |